Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.

Next Previous
Trial Profile

Phase II study of gemcitabine, carboplatin and VELIPARIB (ABT-888) in refractory testicular germ cell cancer.

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carboplatin (Primary) ; Gemcitabine (Primary) ; Veliparib (Primary)
  • Indications Carcinoma; Germ cell and embryonal neoplasms; Germ cell cancer; Seminoma; Teratoma; Testicular cancer
  • Focus Proof of concept; Therapeutic Use

    • Most Recent Events

    • 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
    • 29 May 2021 Status changed to discontinued as 8 patients were alive and progression-free at 12 months among the first 15 patients hence the study was terminated and this study failed to achieve its primary endpoint
    • 29 May 2021 Primary endpoint 12-month PFS (Percentage of patients that will be free of disease progression according to RECIST criteria 12-months after the first administration of the treatment.)has not been met.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top